Home Compare JNJ vs MRK
Stock Comparison · Industry comparison · Drug Manufacturers - General

Johnson & Johnson vs Merck & Co.: Which Stock Looks Stronger in 2026?

Johnson & Johnson holds the cleaner structural position, with the lead spread across growth and stability. Merck still has the edge on valuation, which keeps the comparison from looking entirely one-sided. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

This is not just a one-metric split: both growth and stability materially support the lead. Johnson & Johnson leads by 10 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. JNJ and MRK share the same industry classification.

For a similarity-based comparison, see how Johnson & Johnson and Merck each position within their functional peer groups in AssetNext.

Peer-Relative Score
JNJ
Johnson & Johnson
73
Peer-Score
Signal qualityHigh
vs
MRK
Merck & Co., Inc.
63
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: JNJ vs MRK Profitability 69 62 Stability 86 57 Valuation 69 88 Growth 69 31 JNJ MRK
Gap Ranking
#1 Growth +38
#2 Stability +29
#3 Valuation +19
#4 Profitability +7
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for JNJ and MRK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer JNJMRK Relative valuation Structural strength

Johnson & Johnson looks stronger, but the price setup still looks more supportive for Merck & Co., Inc..

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
On growth, Johnson & Johnson ranks near the top of the group; Merck & Co., Inc. sits in the weaker half.
Stability
On stability, the same pattern holds: both are strong, but Johnson & Johnson still leads clearly.
Growth — Dominant Gap
JNJ
69
MRK
31
Gap+38in favour of JNJ

Earnings growth is one contributing factor within the growth lead.

What keeps the gap from being one-sided

Absolute pricing still looks more supportive for Merck, with a forward P/E that is 7.1 turns lower there.

What this means for the comparison

The lead is built on both growth and stability — though valuation still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the JNJ vs MRK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-stability comparisons

Explore how JNJ and MRK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.